
Kura Oncology Presents Preclinical Data Demonstrating KO-2806’s Potential to Boost Antitumor Effects of KRASᴳ¹² Inhibitors in Non-Small Cell Lung Cancer
Overview Recently, Kura Oncology, Inc. presented preclinical data at the RAS Summit showcasing the potential of their next-generation FTI in combination with KRASG12C inhibitors. The company also announced plans to include KRASG12C-mutant NSCLC in the combination portion of their Phase 1 clinical trial of KO-2806 (FIT-001). Advancements in Cancer Treatment The development of KO-2806 and…